- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
35th Annual Alton Ochsner Award Relating Smoking and Disease Awarded to Mount Sinai Physician
Ochsner Health announced Paul J. Kenny, PhD as the 2020 recipient of the annual Alton Ochsner Award Relating Smoking and Disease, which recognizes scientific research achievements that provide major insights into the biological mechanisms relating tobacco smoking and human disease.
July 8, 2020—Ochsner Health, Louisiana's largest non-profit academic healthcare system, annouced Paul J. Kenny, PhD, as the recipient of the 35th annual Alton Ochsner Award Relating Smoking and Disease. Kenny is a Ward-Coleman professor and chair of the Nash Family Department of Neuroscience at the Icahn School of Medicine at Mount Sinai in new York.
The award is named after Alton Ochsner, MD, who, in 1939, published the first evidence indicating tobacco smoking was the makor cause of lung cancer. Kenny's research focused on nicotine addiction and provided insights for the development of new treatment methods. In particular, Kenny demonstrated the relevance of glucagon-like peptide to the regulation of nicotine craving.
"As our 2020 honoree, Dr. Kenny joins the ranks of other research giants in this field for his contributions studying nicotine addition,” said Leonardo Seoane, MD, chief academic officer of Ochsner Health.
Read the full press release here.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
